Table 2.
Incidence Rates and Adjusted HRs for Acute CVE Among Transgender Individuals With GAHT Compared With Matched Reference Cohorts19
| Event | Transgender cohort | Adjusted HR (95% CI) | ||
|---|---|---|---|---|
| No. acute CVEs |
Incidence rate per 1,000 person-years (95% CI) |
vs. reference men (cisgender men) |
vs. reference women (cisgender women) |
|
| Transgender women | ||||
| Transgender women overall cohort (n=2,842) | ||||
| VTE | 61 | 5.5 (4.3–7.0) | 1.9 (1.4–2.7) | 2.0 (1.4–2.8) |
| Ischemic stroke | 54 | 4.8 (3.7–6.3) | 1.2 (0.9–1.7) | 1.9 (1.3–2.6) |
| MI | 33 | 2.9 (2.1–4.1) | 0.9 (0.6–1.5) | 1.8 (1.1–2.9) |
| Transgender women estrogen initiation cohort (n=853) | ||||
| VTE | 17 | 6.6 (4.1–10.6) | 3.2 (1.5–6.5) | 2.5 (1.2–5.0) |
| At 0–2 years of follow-up | 6 | 4.3 (1.9–9.6) | 1.5 (0.5–5.1) | 1.7 (0.5–5.5) |
| At >2 years of follow-up | 11 | 9.3 (5.2–16.8) | 5.1 (2.1–12.6) | 3.2 (1.3–7.6) |
| Ischemic stroke | 17 | 6.6 (4.1–10.6) | 2.3 (1.2–4.3) | 2.9 (1.5–5.5) |
| At 0–6 years of follow-up | 9 | 3.8 (2.0–7.3) | 1.3 (0.6–2.9) | 2.3 (1.0–5.4) |
| At >6 years of follow-up | 8 | 36.2 (18.1–72.4) | 9.9 (3.0–33.1) | 4.1 (1.5–11.4) |
| MI in the cohort overall | 4 | 1.5 (0.6–4.1) | 1.0 (0.3–3.2) | 2.4 (0.6–9.4) |
| Transgender men | ||||
| Transgender men overall cohort (n=2,118) | ||||
| VTE | 23 | 3.1 (2.0–4.6) | 1.6 (0.9–2.9) | 1.1 (0.6–2.1) |
| Ischemic stroke | 16 | 2.1 (1.3–3.5) | 1.1 (0.6–2.0) | 1.3 (0.7–2.5) |
| MI | 9 | 1.2 (0.6–2.3) | 0.7 (0.3–1.8) | 1.3 (0.5–3.9) |
| Testosterone initiation cohort (n=585) | ||||
| VTE | 4 | 3.3 (1.3–8.9) | 2.7 (0.6–12.1) | 1.5 (0.4–5.6) |
| Ischemic stroke | 2 | 1.7 (0.4–6.7) | Not calculated | Not calculated |
| MI | 0 | – | – | – |
Reproduce with permission from Getahun D, et al.19 CI, confidence interval; CVE, cardiovascular events; GAHT, gender-affirming hormone therapy; HR, hazard ratio; MI, myocardial infarction; VTE, venous thromboembolism.